Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Plus PD-1 Inhibitor and Radiotherapy in Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT07555860Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07555860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555860.